Clinical trials in Poznan – page 31

943 clinical trials in Poznan, Poland across 11 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Poznan at a glance

943

clinical trials

Research sites11

Quick filters

943 trials in Poznan

Open in trial search

Conjunctivitis allergic+3

Not yet recruiting

Efficacy and safety of 6‑grass pollen polymerized extracts 30,000 TU/mL and 10,000 TU/mL in adults with grass pollen‑induced allergic rhinitis/rhinoconjunctivitis, with or without mild‑to‑moderate asthma

Registered drug

Efficacy and safety of 6‑grass pollen polymerized extracts 30,000 TU/mL and 10,000 TU/mL in adults with grass pollen‑induced allergic rhinitis/rhinoconjunctivitis, with or without mild‑to‑moderate asthma

Registered drug

Poland

Participants:0–17 years · 18–64 years
Substances:Bilastine
Sponsor:Inmunotek S.L.

Contact Research Centre

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Dnth103
Sponsor:Dianthus Therapeutics Inc.

Contact Research Centre

Cough

Not yet recruiting

A Randomized Dose‑Ranging Study of Nalbuphine Hydrochloride Extended‑Release Tablets in Adults with Refractory Chronic Cough

Investigational

A Randomized Dose‑Ranging Study of Nalbuphine Hydrochloride Extended‑Release Tablets in Adults with Refractory Chronic Cough

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Nalbuphine Hydrochloride
Sponsor:Trevi Therapeutics Inc.

Contact Research Centre

Colitis ulcerative

Not yet recruiting

Phase 2b Study of ATH-063 in Adults with Biologic‑Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis

Investigational

Phase 2b Study of ATH-063 in Adults with Biologic‑Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis

Investigational

Poland

Participants:18–64 years

Contact Research Centre

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:GSK5733584
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Plasma cell myeloma

Not yet recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Asthma

Not yet recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Sponsor:Kymera Therapeutics Inc.

Contact Research Centre

Cushing's syndrome

Not yet recruiting

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Recordati AG

Contact Research Centre

Chronic graft versus host disease

Not yet recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant

Not yet recruiting

Registered drugNo placebo

A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:AZD0120
Sponsor:AstraZeneca AB

Contact Research Centre

Adenocarcinoma pancreas

Not yet recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Malignant peritoneal neoplasm+2

Not yet recruiting

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Azenosertib
Sponsor:K-Group Beta Inc.

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Poznan

What the registry says about research in the country

01 Immunology & Infectious Diseases

Clinical trials focusing on meningococcal vaccines and respiratory syncytial virus prevention. Studies include testing new conjugate vaccines in infants and evaluating immune responses in older adults.

Meningococcal infection prevention
RSV vaccination studies
Vaccine immunogenicity assessment

Multiple age groups are being studied to ensure comprehensive protection against infectious diseases.

02 Dermatology & Rheumatology

Innovative research into psoriatic conditions and inflammatory skin disorders. Studies evaluating new treatments for plaque psoriasis and psoriatic arthritis.

Moderate to severe plaque psoriasis
Psoriatic arthritis treatments
Atopic dermatitis therapy

Focus on developing targeted therapies for chronic inflammatory skin conditions.

03 Oncology

Advanced research in bladder cancer and other oncological conditions. Studies combining immunotherapy with traditional treatments for enhanced efficacy.

Non-muscle invasive bladder cancer
Metastatic prostate cancer
Gastric cancer treatments

Investigating novel combination therapies and targeted treatments for various cancer types.

04 Chronic Diseases

Comprehensive studies addressing chronic kidney disease, obesity, and cardiovascular conditions. Research focuses on innovative treatment approaches and disease management.

Heart failure prevention
Obesity management
Chronic kidney disease treatment

Evaluating new therapeutic options for long-term disease management and prevention.

Back to Poland All countries